Tanvex BioPharma, Inc. (TPE: 6541)
Taiwan
· Delayed Price · Currency is TWD 68.50
+3.40 (5.22%)
Jan 20, 2025, 1:30 PM CST
Tanvex BioPharma Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Cash & Equivalents | 742.1 | 380.75 | 786.23 | 2,223 | 2,069 | 2,427 | Upgrade
|
| Cash & Short-Term Investments | 742.1 | 380.75 | 786.23 | 2,223 | 2,069 | 2,427 | Upgrade
|
| Cash Growth | -15.07% | -51.57% | -64.63% | 7.46% | -14.78% | -31.18% | Upgrade
|
| Accounts Receivable | 5.58 | 9.4 | 0.33 | 2.52 | - | - | Upgrade
|
| Other Receivables | 30.89 | 27.43 | 27.36 | 25.31 | 25.57 | 1.29 | Upgrade
|
| Receivables | 36.46 | 36.83 | 27.69 | 27.84 | 25.57 | 1.29 | Upgrade
|
| Inventory | 130.81 | 108.29 | 170.84 | 90.33 | 50.08 | 52.2 | Upgrade
|
| Prepaid Expenses | 25.81 | 78.35 | 58.95 | 60.85 | 119.25 | 124.03 | Upgrade
|
| Total Current Assets | 935.18 | 604.21 | 1,044 | 2,402 | 2,264 | 2,605 | Upgrade
|
| Property, Plant & Equipment | 1,830 | 1,928 | 2,151 | 2,114 | 1,906 | 922.96 | Upgrade
|
| Other Intangible Assets | 4.27 | 3.38 | 12.07 | 10.17 | 11.96 | 15.93 | Upgrade
|
| Other Long-Term Assets | 220.67 | 227.67 | 213.47 | 187.58 | 190.98 | 29.13 | Upgrade
|
| Total Assets | 2,990 | 2,763 | 3,420 | 4,714 | 4,373 | 3,573 | Upgrade
|
| Accrued Expenses | 108.17 | - | 115.93 | 137.49 | 210.99 | 179.66 | Upgrade
|
| Current Portion of Long-Term Debt | - | - | - | - | 54.77 | - | Upgrade
|
| Current Portion of Leases | 169.28 | 163.45 | 124.65 | 88.75 | 65.74 | 71.07 | Upgrade
|
| Current Unearned Revenue | 10.71 | 6.91 | 28.07 | - | - | - | Upgrade
|
| Other Current Liabilities | 68.59 | 193.38 | 34.63 | 22.28 | 21.6 | 19.72 | Upgrade
|
| Total Current Liabilities | 356.76 | 363.73 | 303.29 | 248.51 | 353.1 | 270.45 | Upgrade
|
| Long-Term Debt | - | - | - | - | 35.53 | - | Upgrade
|
| Long-Term Leases | 1,478 | 1,568 | 1,715 | 1,670 | 1,363 | 271.67 | Upgrade
|
| Long-Term Unearned Revenue | 6.59 | 10.23 | - | - | - | - | Upgrade
|
| Other Long-Term Liabilities | - | - | 10.47 | - | - | - | Upgrade
|
| Total Liabilities | 1,842 | 1,942 | 2,028 | 1,919 | 1,752 | 542.12 | Upgrade
|
| Common Stock | 1,641 | 1,340 | 3,527 | 3,525 | 3,116 | 2,642 | Upgrade
|
| Additional Paid-In Capital | 13,564 | 12,431 | 11,061 | 10,988 | 9,653 | 8,348 | Upgrade
|
| Retained Earnings | -13,858 | -12,755 | -12,969 | -11,327 | -9,784 | -7,680 | Upgrade
|
| Comprehensive Income & Other | -198.09 | -194.17 | -227.09 | -390.12 | -364.04 | -279.38 | Upgrade
|
| Shareholders' Equity | 1,148 | 821.11 | 1,391 | 2,795 | 2,621 | 3,031 | Upgrade
|
| Total Liabilities & Equity | 2,990 | 2,763 | 3,420 | 4,714 | 4,373 | 3,573 | Upgrade
|
| Total Debt | 1,648 | 1,732 | 1,839 | 1,759 | 1,519 | 342.74 | Upgrade
|
| Net Cash (Debt) | -905.5 | -1,351 | -1,053 | 463.95 | 549.19 | 2,085 | Upgrade
|
| Net Cash Growth | - | - | - | -15.52% | -73.66% | -40.90% | Upgrade
|
| Net Cash Per Share | -6.13 | -10.48 | -8.95 | 4.27 | 6.14 | 25.45 | Upgrade
|
| Filing Date Shares Outstanding | 164.07 | 133.96 | 117.64 | 117.57 | 103.95 | 88.13 | Upgrade
|
| Total Common Shares Outstanding | 164.07 | 133.96 | 117.64 | 117.57 | 103.95 | 88.13 | Upgrade
|
| Working Capital | 578.42 | 240.48 | 740.43 | 2,153 | 1,910 | 2,335 | Upgrade
|
| Book Value Per Share | 7.00 | 6.13 | 11.83 | 23.77 | 25.21 | 34.39 | Upgrade
|
| Tangible Book Value | 1,144 | 817.73 | 1,379 | 2,785 | 2,609 | 3,015 | Upgrade
|
| Tangible Book Value Per Share | 6.97 | 6.10 | 11.73 | 23.68 | 25.10 | 34.21 | Upgrade
|
| Machinery | 1,047 | 982.54 | 975.18 | 889.53 | 884.87 | 863.48 | Upgrade
|
| Construction In Progress | 94.47 | 83.71 | 72.82 | 53.8 | 48.78 | 49.41 | Upgrade
|
| Leasehold Improvements | 448.55 | 415.69 | 388.62 | 318.95 | 322.42 | 340.54 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.